Bank of New York Mellon Corp Increases Position in AstraZeneca plc (AZN)

Bank of New York Mellon Corp lifted its stake in shares of AstraZeneca plc (NYSE:AZN) by 11.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 218,344 shares of the company’s stock after purchasing an additional 22,379 shares during the quarter. Bank of New York Mellon Corp’s holdings in AstraZeneca were worth $7,397,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in AZN. Voya Investment Management LLC grew its holdings in shares of AstraZeneca by 38.2% during the 2nd quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock valued at $81,661,000 after purchasing an additional 662,481 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of AstraZeneca by 4.7% during the 3rd quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after purchasing an additional 519,717 shares during the last quarter. State Street Corp bought a new stake in shares of AstraZeneca during the 2nd quarter valued at approximately $14,536,000. Royal Bank of Canada grew its holdings in shares of AstraZeneca by 12.2% during the 2nd quarter. Royal Bank of Canada now owns 1,855,405 shares of the company’s stock valued at $63,250,000 after purchasing an additional 201,885 shares during the last quarter. Finally, Skba Capital Management LLC bought a new stake in shares of AstraZeneca during the 2nd quarter valued at approximately $6,462,000. 14.75% of the stock is currently owned by institutional investors.

AZN has been the topic of a number of research reports. Sanford C. Bernstein reissued a “buy” rating on shares of AstraZeneca in a report on Friday, September 22nd. Argus reissued a “buy” rating and set a $35.00 target price on shares of AstraZeneca in a report on Friday, September 1st. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Wednesday, November 15th. BNP Paribas raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Finally, Leerink Swann boosted their target price on shares of AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Four analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $34.20.

AstraZeneca plc (AZN) opened at $34.11 on Friday. The stock has a market cap of $85,377.76, a P/E ratio of 8.05, a PEG ratio of 3.07 and a beta of 0.72. AstraZeneca plc has a 1 year low of $26.51 and a 1 year high of $35.60. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.55. The firm had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 EPS. equities research analysts forecast that AstraZeneca plc will post 1.87 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/29/bank-of-new-york-mellon-corp-increases-position-in-astrazeneca-plc-azn.html.

AstraZeneca Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

What are top analysts saying about AstraZeneca? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit